Clinical and laboratory rationale for use of correctors of metabolism for treatment of patients with new coronavirus infection COVID-19 in acute period with background of cerebrovascular disease
- 8 June 2022
- journal article
- research article
- Published by Alfmed LLC in Medical alphabet
- No. 10,p. 12-16
Abstract
Objective. The aim of the study was to evaluate the effectiveness of the drug Mildronate in the complex therapy of patients with a new coronavirus infection COVID-19 in the acute period and the background of cerebrovascular disease.Material and methods. The material for the study was the medical records of 210 patients (140 women and 70 men) who had COVID-19 coronavirus infection against the background of cerebrovascular pathology in the period from 04.10.2020 to 12.31.2021. 120 patients (75 women and 45 men) received the drug Mildronate as part of complex therapy, 90 patients (55 women 35 men) made up the control group, received complex treatment without the use of the drug Mildronate. Patients in both groups were comparable in age, the average age was 76.5 years (from 50 to 93 years). Groups according to nosological forms were distributed as follows: in the main group – ischemic stroke of various localization – 70 patients (48 women and 22 men), chronic cerebrovascular insufficiency of varying severity – 50 patients (27 women and 23 men); in the control group – ischemic stroke of various localization was in 50 patients (36 women and 14 men), chronic cerebrovascular insufficiency – 40 patients (19 women and 21 men). To correct chronic hypoxia, the drug Mildronate was chosen, which is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation under conditions of ischemia and hypoxia. Also, Mildronate is one of the universal cytoprotectors with a pronounced neuro-, cardio- and angioprotective effect, which goes well with drugs of other pharmacological groups.Results. The drug Mildronate is a blocker of fatty acid oxidation, has a multicomponent effect, stabilizes microcirculation in conditions of ischemia and hypoxia. According to the observations, it can be noted that the neurological status during mildronate therapy has a more significant regression trend with good rehabilitation potential – 56.0% of patients can serve themselves independently, while patients in the control group reached a level of 9 points only in 51.0% of cases. A significant neurological defect remained in the main group in 6.2% of patients, in the control group this figure was 8.8%.Keywords
This publication has 14 references indexed in Scilit:
- Protective Effects of Meldonium in Experimental Models of Cardiovascular Complications with a Potential Application in COVID-19International Journal of Molecular Sciences, 2021
- New data on well-known drug: focus on meldoniumMeditsinskiy sovet = Medical Council, 2021
- Differentiated approach to treatment of cognitive disorders associated with SARS-CoV-2 (COVID-19), taking into account comorbidity factorMedical alphabet, 2021
- Antioxidants: Classification, Natural Sources, Activity/Capacity Measurements, and Usefulness for the Synthesis of NanoparticlesMaterials, 2021
- Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19Antioxidants, 2021
- The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’Neurology, Neuropsychiatry, Psychosomatics, 2021
- Role of antioxidant therapy in patients with moderate and severe COVID-19Infekcionnye bolezni, 2021
- COVID-19: Oxidative Preconditioning as a Potential Therapeutic ApproachACS Chemical Neuroscience, 2020
- Options of metabolic support in case of coronaviral infectionTherapy, 2020
- COVID-19: oxidative stress and the relevance of antioxidant therapyAnnals of the Russian academy of medical sciences, 2020